🏛️ Verified NIH Record • Updated 2026-07-16

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors (NCT07205718)

An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Takeda

🩺 Plain-English Summary (8th-Grade Level)

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.

Who can join: Review the eligibility criteria below.

Location: UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica) — Santa Monica, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (15 Sites)

  • UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica) — Santa Monica, California
  • Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers — New Haven, Connecticut
  • Florida Cancer Specialists - Lake Nona — Orlando, Florida
  • Johns Hopkins — Baltimore, Maryland
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
  • START Midwest — Grand Rapids, Michigan
  • Washington University — St Louis, Missouri
  • University Hospitals Cleveland Medical Center — Cleveland, Ohio
  • Providence Cancer Institute, Franz Clinic — Portland, Oregon
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
  • SCRI Oncology — Nashville, Tennessee
  • MD Anderson Cancer Center — Houston, Texas
  • NEXT Dallas — Irving, Texas
  • START San Antonio — San Antonio, Texas
  • NEXT Virginia — Fairfax, Virginia

📞 Contact the Study Coordinator

Phone: (877) 825-3327

Email: medinfoUS@takeda.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced or Metastatic Solid Tumors

Explore by condition: All Advanced or Metastatic Solid Tumors clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗